<p>阿伯丁集团 plc 在最近向证券交易委员会的披露中表示，在第三季度将其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免费报告）中的持股增加了 21.3%。该公司在此期间购买了额外的 59,602 股后，持有该公司 339,949 股股票。截至最近向证券交易委员会的备案，阿伯丁集团 plc 拥有约 0.36% 的 Crinetics Pharmaceuticals，价值 14,159,000 美元。</p>
<p>其他一些机构投资者最近也买卖了该公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 11.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 59,311 股该公司的股票，价值 1,995,000 美元，此前在此期间购买了额外的 6,148 股。瑞银资产管理美国有限公司的一个独立业务部门在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 6.9%。瑞银资产管理美国有限公司的这个独立业务部门目前拥有 347,581 股该公司的股票，价值 11,658,000 美元，此前在此期间购买了额外的 22,305 股。Strs Ohio 在第一季度获得了 Crinetics Pharmaceuticals 的新头寸，价值约 124,000 美元。AlphaQuest LLC 在第二季度获得了 Crinetics Pharmaceuticals 的新股份，价值 799,000 美元。最后，新泽西州共同养老金基金 D 在第二季度将其在 Crinetics Pharmaceuticals 的持股增加了 11.9%。新泽西州共同养老金基金 D 目前拥有 62,552 股该公司的股票，价值 1,799,000 美元，此前在上个季度购买了额外的 6,674 股。当前 98.51% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>几位研究分析师对 CRNX 股票发表了看法。高盛集团在 1 月 12 日的研究报告中将 Crinetics Pharmaceuticals 的评级从 “中性” 上调至 “买入”，并设定了 67.00 美元的目标价。华尔街 Zen 在 2 月 14 日的研究报告中将 Crinetics Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。Lifesci Capital 在 2 月 13 日的研究报告中将 Crinetics Pharmaceuticals 的评级上调至 “强力买入”。Citizens Jmp 在 1 月 8 日的报告中将 Crinetics Pharmaceuticals 的目标价从 108.00 美元下调至 105.00 美元，并为该公司设定了 “市场表现优于大盘” 的评级。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Crinetics Pharmaceuticals 的 “卖出（d-）” 评级。一位分析师对该股票给予了强力买入评级，九位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Crinetics Pharmaceuticals 当前的平均评级为 “适度买入”，共识目标价为 75.78 美元。</p>
<p><strong>查看我们关于 Crinetics Pharmaceuticals 的最新股票报告</strong></p>
<h2>Crinetics Pharmaceuticals 价格表现</h2>
<p>CRNX 周五开盘价为 44.00 美元。该公司的市值为 45 亿美元，市盈率为 -9.71，贝塔值为 0.19。该公司的 50 日移动平均价格为 49.42 美元，200 日移动平均价格为 42.47 美元。Crinetics Pharmaceuticals, Inc. 的 52 周低点为 24.10 美元，52 周高点为 57.99 美元。</p>
<h2>Crinetics Pharmaceuticals 的内部活动</h2>
<p>在相关消息中，内部人士 Isabel Kalofonos 于 1 月 5 日星期一出售了 2,500 股该公司的股票。该股票以平均价格 55.00 美元出售，总交易额为 137,500.00 美元。交易完成后，内部人士在公司中持有 834 股，价值 45,870 美元。此交易代表其持股减少了 74.99%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。4.60% 的股票由公司内部人士持有。</p>
<h2>关于 Crinetics Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Crinetics Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于治疗罕见内分泌疾病的新型治疗药物。该公司的专有平台利用对激素受体信号传导的洞察，设计小分子候选药物，以应对由激素活动失调引起的疾病。Crinetics 的研究工作集中在针对生长抑素、抗利尿激素和其他 GPCR 介导的通路，开发口服生物可用的分子，以提高患者的便利性和依从性。</p>
<p>该公司的主要产品候选药物 paltusotine（前称 CRN04777）是一种选择性非肽类生长抑素受体 2 型激动剂，正在评估用于治疗肢端肥大症和类癌综合症腹泻。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Crinetics Pharmaceuticals</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>我的爱泼斯坦故事</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><strong>想看看其他对冲基金持有的 CRNX 吗？</strong> 访问 HoldingsChannel.com 获取 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免费报告）的最新 13F 备案和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Crinetics Pharmaceuticals 吗？</h2>
<p>在考虑投资 Crinetics Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Crinetics Pharmaceuticals 并不在名单上。</p>
<p>尽管 Crinetics Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医疗业 ETF - SPDR

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

<p>阿伯丁集团 plc 在第三季度将其在 Crinetics Pharmaceuticals, Inc. 的股份增加了 21.3%，目前持有 339,949 股，价值 1416 万美元。其他机构投资者也调整了他们的持股。分析师对 CRNX 的评级不一，高盛将其评级上调至 “买入”，并设定目标价为 67.00 美元。该股票开盘价为 44.00 美元，市值为 45 亿美元。内部人士 Isabel Kalofonos 出售了 2,500 股，显著减少了她的持股。Crinetics 专注于开发针对罕见内分泌疾病的治疗药物</p>

<p>Aberdeen Group plc boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 339,949 shares of the company's stock after buying an additional 59,602 shares during the period. Aberdeen Group plc owned approximately 0.36% of Crinetics Pharmaceuticals worth $14,159,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>阿伯丁集团 plc 在最近向证券交易委员会的披露中表示，在第三季度将其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免费报告）中的持股增加了 21.3%。该公司在此期间购买了额外的 59,602 股后，持有该公司 339,949 股股票。截至最近向证券交易委员会的备案，阿伯丁集团 plc 拥有约 0.36% 的 Crinetics Pharmaceuticals，价值 14,159,000 美元。</p>
</div><p>A number of other institutional investors have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals by 11.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company's stock valued at $1,995,000 after purchasing an additional 6,148 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Crinetics Pharmaceuticals by 6.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company's stock worth $11,658,000 after purchasing an additional 22,305 shares during the period. Strs Ohio acquired a new position in Crinetics Pharmaceuticals in the 1st quarter valued at approximately $124,000. AlphaQuest LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the 2nd quarter valued at $799,000. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Crinetics Pharmaceuticals by 11.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,552 shares of the company's stock valued at $1,799,000 after acquiring an additional 6,674 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了该公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 11.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 59,311 股该公司的股票，价值 1,995,000 美元，此前在此期间购买了额外的 6,148 股。瑞银资产管理美国有限公司的一个独立业务部门在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 6.9%。瑞银资产管理美国有限公司的这个独立业务部门目前拥有 347,581 股该公司的股票，价值 11,658,000 美元，此前在此期间购买了额外的 22,305 股。Strs Ohio 在第一季度获得了 Crinetics Pharmaceuticals 的新头寸，价值约 124,000 美元。AlphaQuest LLC 在第二季度获得了 Crinetics Pharmaceuticals 的新股份，价值 799,000 美元。最后，新泽西州共同养老金基金 D 在第二季度将其在 Crinetics Pharmaceuticals 的持股增加了 11.9%。新泽西州共同养老金基金 D 目前拥有 62,552 股该公司的股票，价值 1,799,000 美元，此前在上个季度购买了额外的 6,674 股。当前 98.51% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research analysts have weighed in on CRNX shares. The Goldman Sachs Group raised Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a research report on Monday, January 12th. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, February 14th. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Friday, February 13th. Citizens Jmp decreased their price objective on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a &#34;market outperform&#34; rating for the company in a report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $75.78.</p>
<div class="lb-trans"><p>几位研究分析师对 CRNX 股票发表了看法。高盛集团在 1 月 12 日的研究报告中将 Crinetics Pharmaceuticals 的评级从 “中性” 上调至 “买入”，并设定了 67.00 美元的目标价。华尔街 Zen 在 2 月 14 日的研究报告中将 Crinetics Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。Lifesci Capital 在 2 月 13 日的研究报告中将 Crinetics Pharmaceuticals 的评级上调至 “强力买入”。Citizens Jmp 在 1 月 8 日的报告中将 Crinetics Pharmaceuticals 的目标价从 108.00 美元下调至 105.00 美元，并为该公司设定了 “市场表现优于大盘” 的评级。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Crinetics Pharmaceuticals 的 “卖出（d-）” 评级。一位分析师对该股票给予了强力买入评级，九位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Crinetics Pharmaceuticals 当前的平均评级为 “适度买入”，共识目标价为 75.78 美元。</p>
</div><p><strong>View Our Latest Stock Report on Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Crinetics Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Crinetics Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 价格表现</h2>
</div><p>CRNX opened at $44.00 on Friday. The company has a market capitalization of $4.50 billion, a P/E ratio of -9.71 and a beta of 0.19. The firm's fifty day moving average price is $49.42 and its two-hundred day moving average price is $42.47. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $24.10 and a fifty-two week high of $57.99.</p>
<div class="lb-trans"><p>CRNX 周五开盘价为 44.00 美元。该公司的市值为 45 亿美元，市盈率为 -9.71，贝塔值为 0.19。该公司的 50 日移动平均价格为 49.42 美元，200 日移动平均价格为 42.47 美元。Crinetics Pharmaceuticals, Inc. 的 52 周低点为 24.10 美元，52 周高点为 57.99 美元。</p>
</div><h2>Insider Activity at Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的内部活动</h2>
</div><p>In related news, insider Isabel Kalofonos sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the transaction, the insider owned 834 shares in the company, valued at $45,870. This trade represents a 74.99% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Isabel Kalofonos 于 1 月 5 日星期一出售了 2,500 股该公司的股票。该股票以平均价格 55.00 美元出售，总交易额为 137,500.00 美元。交易完成后，内部人士在公司中持有 834 股，价值 45,870 美元。此交易代表其持股减少了 74.99%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。4.60% 的股票由公司内部人士持有。</p>
</div><h2>About Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Crinetics Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于治疗罕见内分泌疾病的新型治疗药物。该公司的专有平台利用对激素受体信号传导的洞察，设计小分子候选药物，以应对由激素活动失调引起的疾病。Crinetics 的研究工作集中在针对生长抑素、抗利尿激素和其他 GPCR 介导的通路，开发口服生物可用的分子，以提高患者的便利性和依从性。</p>
</div><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 paltusotine（前称 CRN04777）是一种选择性非肽类生长抑素受体 2 型激动剂，正在评估用于治疗肢端肥大症和类癌综合症腹泻。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>My Epstein Story</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Crinetics Pharmaceuticals</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>我的爱泼斯坦故事</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CRNX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 CRNX 吗？</strong> 访问 HoldingsChannel.com 获取 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免费报告）的最新 13F 备案和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Crinetics Pharmaceuticals 吗？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Crinetics Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Crinetics Pharmaceuticals 并不在名单上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Crinetics Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX

Market Beat

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

Crinetics Pharmaceuticals

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

阿伯丁集团有限公司持有 Crinetics Pharmaceuticals, Inc. $CRNX 价值 1416 万美元的股票